REVIEW PAPER
BROAD SPECTRUM OF THERAPEUTIC PROPERTIES OF PSILOCYBIN:
A LITERATURE REVIEW
1
Faculty of Medical Sciences in Katowice, Medical University of Silesia, Poland
2
St. Luke's Provincial Hospital in Tarnów, Poland
3
Katowice Oncology Center, Katowice, Poland
Submission date: 2024-10-01
Final revision date: 2025-01-17
Acceptance date: 2025-01-20
Publication date: 2025-02-20
Corresponding author
Julia Wójcik
Julia Wójcik, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Poniatowskiego 15, 40-055 Katowice, Poland
Julia Wójcik, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Poniatowskiego 15, 40-055 Katowice, Poland
KEYWORDS
TOPICS
ABSTRACT
Psilocybin is a psychoactive chemical compound found in the mushrooms of the Psilocybe genus which have gained significant popularity over the past decade due to their impact on neuroplasticity, serotonergic action, and their ability to create new connections between areas that previously did not communicate with each other. The aim of the study was to assess the potential applications of psilocybin in the treatment of mental illnesses. The article was developed using PubMed and Google Scholar, focusing on articles published after 2021. Psilocybin is considered an alternative therapeutic option for treating mental health disorders such as: depression, anxiety, addictions, post-traumatic stress disorder, obsessive-compulsive disorder, and anorexia. Studies show that even a single dose or several small doses, combined with psychotherapy, can bring rapid benefits lasting for months. Psilocybin offers a promising alternative for patients with treatment failures, side effects, or unsuitable traditional treatments. It can also be used in healthy patients with impotence. Psilocybin demonstrates the best safety profile among other psychedelics. It does not cause life-threatening side effects, and it has few contraindications. More scientific research is needed to establish treatment standards for psilocybin, which would thus allow the introduction of hallucinogens into everyday clinical practice.
REFERENCES (56)
1.
COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398(10312): 1700-1712. https://doi.org/10.1016/S0140-....
2.
Tylš F, Páleníček T, Horáček J. Psilocybin-summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014; 24(3): 342-56. https://doi.org/10.1016/j.euro....
3.
Goel DB, Zilate S. Potential therapeutic effects of psilocybin: a systematic review. Cureus. 2022; 14(10): e30214. https://doi.org/10.7759/cureus....
4.
Smausz R, Neill J, Gigg J. Neural mechanisms underlying psilocybin's therapeutic potential – the need for preclinical in vivo electrophysiology. J Psychopharmacol. 2022; 36(7): 781-793. https://doi.org/10.1177/026988....
5.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The therapeutic potential of psilocybin. Molecules. 2021; 26(10): 2948. https://doi.org/10.3390/molecu....
6.
Yu Z, Burback L, Winkler O, Xu L, Dennett L, Vermetten E, et al. Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review. Front Psychiatry. 2024; 15: 1386321. https://doi.org/10.3389/fpsyt.....
7.
Reed F, Foldi CJ. Do the therapeutic effects of psilocybin involve actions in the gut?. Trends Pharmacol Sci. 2024; 45(2): 107-117. https://doi.org/10.1016/j.tips....
8.
Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Netw Open. 2024; 7(4): e245960. https://doi.org/10.1001/jamane....
9.
Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022; 36(2): 151-158. https://doi.org/10.1177/026988....
10.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021; 384(15): 1402-1411. https://doi.org/10.1056/NEJMoa....
11.
Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024; 385: e078084. https://doi.org/10.1136/bmj-20....
12.
Dawood Hristova JJ, Pérez-Jover V. Psychotherapy with psilocybin for depression: systematic review. Behav Sci (Basel). 2023; 13(4): 297.. https://doi.org/10.3390/bs1304....
13.
Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023; 330(9): 843-853. https://doi.org/10.1001/jama.2....
14.
Olivier B, Olivier JDA. Efficacy, Safety, and tolerability of psychedelics in treatment-resistant depression (TRD). Adv Exp Med Biol. 2024; 1456: 49-66. https://doi.org/10.1007/978-98....
15.
von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022; 56: 101809. https://doi.org/10.1016/j.ecli....
16.
Lyons A. Self-administration of psilocybin in the setting of treatment-resistant depression. Innov Clin Neurosci. 2022; 19(7-9): 44-47.
17.
Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M. Esketamine and psilocybin – the comparison of two mind-altering agents in depression treatment: systematic review. Int J Mol Sci. 2022; 23(19): 11450. https://doi.org/10.3390/ijms23....
18.
Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, et al. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Sci Rep. 2024; 14(1): 2929. https://doi.org/10.1038/s41598....
19.
Harari R, Chatterjee I, Getselter D, Elliott E. Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor. iScience. 2024; 27(5): 109686. https://doi.org/10.1016/j.isci....
20.
King F, Hammond R. Psychedelics as reemerging treatments for anxiety disorders: possibilities and challenges in a nascent field. Focus (Am Psychiatr Publ). 2021; 19(2): 190-196. https://doi.org/10.1176/appi.f....
21.
Feulner L, Sermchaiwong T, Rodland N, Galarneau D. Efficacy and safety of psychedelics in treating anxiety disorders. Ochsner J. 2023; 23(4): 315-328. https://doi.org/10.31486/toj.2....
22.
Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC, et al. Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis. Psychiatry Investig. 2021; 18(10): 958-967. https://doi.org/10.30773/pi.20....
23.
Naulls S, Bunn S. Psychedelic-assisted therapy to treat anxiety disorders [Internet]. UK Parliament; 2024 Feb 5 [cited 2024 Sep 15]. Available from: https://doi.org/10.58248/RR10.
24.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016; 30(12): 1181-1197. https://doi.org/10.1177/026988....
25.
Bogadi M, Kaštelan S. A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. Croat Med J. 2021; 62(5): 528-530. https://doi.org/10.3325/cmj.20....
26.
McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022; 21(6): 463-73. https://doi.org/10.1038/s41573....
27.
van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, et al. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023; 14: 1134454. https://doi.org/10.3389/fpsyt.....
28.
Jones G, Lipson J, Nock MK. Associations between classic psychedelics and nicotine dependence in a nationally representative sample. Sci Rep. 2022; 12: 10578. https://doi.org/10.1038/s41598....
29.
Spoelstra SK, Schoevers RA, Venema SD, Knegtering H. Psychedelics as a potential treatment for tobacco use disorder: a systematic review. Discov Ment Health. 2024; 4: 37. https://doi.org/10.1007/s44192....
30.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015; 29(3): 289-99. https://doi.org/10.1177/026988....
31.
Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022; 79(10): 953-962. https://doi.org/10.1001/jamaps....
32.
Benvenuti F, Colombo D, Soverchia L, Cannella N, Domi E, Ciccocioppo R. Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories. Psychopharmacology (Berl). 2023; 240(7): 1521-1530. https://doi.org/10.1007/s00213....
33.
Biscoe N, Bonson A, Slavin M, Busuttil W, MacManus D, Cox A, et al. Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: a feasibility study protocol. Eur J Trauma Dissoc. 2023; 7(4): 100359. https://doi.org/10.1016/j.ejtd....
34.
Modlin NL, Creed M, Sarang M, Maggio C, Rucker JJ, Williamson V. Trauma-informed care in psychedelic therapy research: a qualitative literature review of evidence-based psychotherapy interventions in PTSD and psychedelic therapy across conditions. Neuropsychiatr Dis Treat. 2024; 20: 109-135. https://doi.org/10.2147/NDT.S4....
35.
Henner RL, Keshavan MS, Hill KP. Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022; 439: 120302. https://doi.org/10.1016/j.jns.....
36.
Woodburn SC, Levitt CM, Koester AM, Kwan AC. Psilocybin facilitates fear extinction: importance of dose, context, and serotonin receptors. ACS Chem Neurosci. 2024;1 5(16): 3034-3043. https://doi.org/10.1021/acsche....
37.
Averill LA, Abdallah CG. Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. Expert Opin Investig Drugs. 2022; 31(2): 133-137. https://doi.org/10.1080/135437....
38.
Du Y, Li Y, Zhao X, Yao Y, Wang B, Zhang L, et al. Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. Chin Med J (Engl). 2023; 136(24): 2983-2992. https://doi.org/10.1097/CM9.00....
39.
Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020; 27: 100538. https://doi.org/10.1016/j.ecli....
40.
Norred MA, Zuschlag ZD, Hamner MB. A neuroanatomic and pathophysiologic framework for novel pharmacological approaches to the treatment of post-traumatic stress disorder. Drugs. 2024; 84(2): 149-164. https://doi.org/10.1007/s40265....
41.
Attia E, Steinglass JE. Psilocybin for anorexia nervosa: if it helps, let's learn how. Med. 2023; 4(9): 581-2. https://doi.org/10.1016/j.medj....
42.
Peck SK, Shao S, Gruen T, Yang K, Babakanian A, Trim J, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023; 29(8): 1947-1953. https://doi.org/10.1038/s41591....
43.
Majić T, Ehrlich S. Psilocybin for the treatment of anorexia nervosa. Nat Med. 2023; 29(8): 1906-1907. https://doi.org/10.1038/s41591....
44.
Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, et al. Use of selective alternative therapies for treatment of OCD. Neuropsychiatr Dis Treat. 2023; 19: 721-732. https://doi.org/10.2147/NDT.S4....
45.
Owe-Larsson M, Kamińska K, Buchalska B, Mirowska-Guzel D, Cudnoch-Jędrzejewska A. Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacol Rep. 2024;76(5):911-925. doi:10.1007/s43440-024-00633.
46.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006; 67(11): 1735-40. https://doi.org/10.4088/JCP.v6....
47.
Roscoe J, Lozy O. Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Sci Policy Law. 2022; 8. https://doi.org/10.1177/205032....
48.
Frecska E. Therapeutic guidelines: dangers and contra-indications in therapeutic applications of hallucinogens. In: Roberts T, Winkelman M, editors. Psychedelic medicine. Westport, CT: Praeger; 2007. p. 69-95.
49.
Zeifman RJ, Kettner H, Pagni BA, Mallard A, Roberts DE, Erritzoe D, et al. Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Sci Rep. 2023; 13(1): 13645. https://doi.org/10.1038/s41598....
50.
Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022; 36(8): 965-973. https://doi.org/10.1177/026988....
51.
Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol. 2016; 30(12): 1268-1278. https://doi.org/10.1177/026988....
52.
Franz M, Regele H, Kirchmair M, Kletzmayr J, Sunder-Plassmann G, Hörl WH, et al. Magic mushrooms: hope for a 'cheap high' resulting in end-stage renal failure. Nephrol Dial Transplant. 1996; 11(11): 2324-27. https://doi.org/10.1093/oxford....
53.
van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 2011; 59(3): 423-9. https://doi.org/10.1016/j.yrtp....
54.
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018; 142: 143-166. https://doi.org/10.1016/j.neur....
55.
Barba T, Kettner H, Radu C, Peill JM, Roseman L, Nutt DJ, et al. Psychedelics and sexual functioning: a mixed-methods study. Sci Rep. 2024;1 4(2181). https://doi.org/10.1038/s41598....
56.
Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, et al. The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. J Psychopharmacol. 2022; 36(1): 114-125. https://doi.org/10.1177/026988....
| eISSN: | 2354-0265 |
| ISSN: | 2353-6942 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
